<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001840315</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001314102</issuerCik>
      <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
      <secFileNumber>000-51122</secFileNumber>
      <issuerAddress>
        <com:street1>480 PLEASANT STREET</com:street1>
        <com:street2>SUITE B300</com:street2>
        <com:city>WATERTOWN</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02472</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-926-5000</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Ocumension Therapeutics</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Tiger Brokers (Singapore) Pte. Ltd.</name>
        <address>
          <com:street1>1 Raffles Place, #35-61</com:street1>
          <com:street2>One Raffles Place Tower 2</com:street2>
          <com:city>Singapore</com:city>
          <com:stateOrCountry>U0</com:stateOrCountry>
          <com:zipCode>04861</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1000000</noOfUnitsSold>
      <aggregateMarketValue>18340000.00</aggregateMarketValue>
      <noOfUnitsOutstanding>35309432</noOfUnitsOutstanding>
      <approxSaleDate>12/05/2023</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common stock</securitiesClassTitle>
      <acquiredDate>12/31/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Through a private placement by the issuer of the securities</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Eyepoint Pharmaceuticals, Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>3010722</amountOfSecuritiesAcquired>
      <paymentDate>12/31/2020</paymentDate>
      <natureOfPayment>Good funds</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>12/05/2023</noticeDate>
      <signature>/s/ Ye Liu</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2929}]
144
0001840315
XXXXXXXX
LIVE
0001314102
EyePoint Pharmaceuticals, Inc.
000-51122
480 PLEASANT STREET
SUITE B300
WATERTOWN
MA
02472
617-926-5000
Ocumension Therapeutics
Director
Common Stock
Tiger Brokers (Singapore) Pte. Ltd.
1 Raffles Place, #35-61
One Raffles Place Tower 2
Singapore
U0
04861
1000000
18340000.00
35309432
12/05/2023
NASDAQ
Common stock
12/31/2020
Through a private placement by the issuer of the securities
Eyepoint Pharmaceuticals, Inc.
N
3010722
12/31/2020
Good funds
Y
12/05/2023
/s/ Ye Liu